Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control

Abstract excerpt

The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5+/6+ PCR, with a genotyping readout as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV) types. LMNX is additionally provided with an internal control probe. Here, we present an analysis of the clinical performance of the LMNX using a sample panel and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacteriophages and microbial interactions
• Share to Cervical Cancer and HPV Research
• Share to Molecular Biology Techniques and Applications